EKF: Stable H1 2026 results with improved margins, strong Life Sciences growth, and robust outlook

Revenue and gross margin remained stable in H1 2026, with adjusted EBITDA growth and strong Life Sciences performance. The order book supports confidence in meeting FY 2026 guidance, while share buybacks and strategic investments continue.Original document: EKF Diagnostics Holdings plc [EKF] Interi…